TY - JOUR
T1 - Hepatitis C knowledge among new injection drug users
AU - Jost, John J.
AU - Goldsamt, Lloyd A.
AU - Harocopos, Alex
AU - Kobrak, Paul
AU - Clatts, Michael C.
N1 - Funding Information:
This study was supported by Grant R01-DA14234 from the National Institute on Drug Abuse. The authors thank Christopher Alley for his contributions to the study.
PY - 2010/12
Y1 - 2010/12
N2 - Aims: New injection drug users (IDUs) are vulnerable to hepatitis C infection from risky injection practices. This article considers the range of hepatits C virus (HCV) knowledge among participants in a 2-year study examining the behaviours of new IDUs. Methods: Respondents (n 36) were members of a cohort of new IDUs recruited in the New York City metropolitan area whose first injection occurred within the previous 18 months. Respondents were offered human immuno virus (HIV), hepatits B virus (HBV) and HCV testing. Two tested HIV positive and 12 tested HCV positive. During pre-test counselling they completed a qualitative interview focusing on aspects of HCV including: transmission, symptoms, long-term effects, prevention, treatment, concern regarding contracting HCV and how this concern impacted drug use and injection practices. Findings: Substantial gaps were seen in HCV knowledge. While respondents were aware that HCV is a blood-borne virus, the majority had only approximate knowledge regarding transmission, symptoms and effects. Respondents reported little discussion of HCV with peers and minimal concern about contracting HCV, especially compared with HIV. Conclusion: Accurate HCV information is failing to reach new IDUs, and new IDUs may not value the little information they do receive. More effective and innovative efforts are required to disseminate effective HCV prevention information to new IDUs.
AB - Aims: New injection drug users (IDUs) are vulnerable to hepatitis C infection from risky injection practices. This article considers the range of hepatits C virus (HCV) knowledge among participants in a 2-year study examining the behaviours of new IDUs. Methods: Respondents (n 36) were members of a cohort of new IDUs recruited in the New York City metropolitan area whose first injection occurred within the previous 18 months. Respondents were offered human immuno virus (HIV), hepatits B virus (HBV) and HCV testing. Two tested HIV positive and 12 tested HCV positive. During pre-test counselling they completed a qualitative interview focusing on aspects of HCV including: transmission, symptoms, long-term effects, prevention, treatment, concern regarding contracting HCV and how this concern impacted drug use and injection practices. Findings: Substantial gaps were seen in HCV knowledge. While respondents were aware that HCV is a blood-borne virus, the majority had only approximate knowledge regarding transmission, symptoms and effects. Respondents reported little discussion of HCV with peers and minimal concern about contracting HCV, especially compared with HIV. Conclusion: Accurate HCV information is failing to reach new IDUs, and new IDUs may not value the little information they do receive. More effective and innovative efforts are required to disseminate effective HCV prevention information to new IDUs.
UR - http://www.scopus.com/inward/record.url?scp=77958612732&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958612732&partnerID=8YFLogxK
U2 - 10.3109/09687630902858948
DO - 10.3109/09687630902858948
M3 - Article
AN - SCOPUS:77958612732
SN - 0968-7637
VL - 17
SP - 821
EP - 834
JO - Drugs: Education, Prevention and Policy
JF - Drugs: Education, Prevention and Policy
IS - 6
ER -
